| 1 |
Breyer MD, Coffman TM, Flessner MF, et al. Diabetic nephropathy: a national dialogue [J]. Clin J Am Soc Nephrol, 2013, 8 (9): 1603-1605.
|
| 2 |
Liu ZH. Nephrology in China [J]. Nat Rev Nephrol, 2013, 9 (9): 523-528.
|
| 3 |
Sandbaek A, Griffin SJ, Sharp SJ, et al. Effect of early multifactorial therapy compared with routine care on microvascular outcomes at 5 years in people with screen-detected diabetes: a randomized controlled trial: the ADDITION-Europe Study [J]. Diabetes Care, 2014, 37 (7): 2015-2023.
|
| 4 |
Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study [J]. BMJ, 2000, 321 (7258): 405-412.
|
| 5 |
Zhang Y, Hu G, Yuan Z, et al. Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and meta-analysis [J]. PLoS One, 2012, 7 (8): e42551.
|
| 6 |
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus [J]. N Engl J Med, 1993, 329 (14): 977-986.
|
| 7 |
de Boer IH, Sun W, Cleary PA, et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes [J]. N Engl J Med, 2011, 365 (25): 2366-2376.
|
| 8 |
Udell JA, Cavender MA, Bhatt DL, et al. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials [J]. Lancet Diabetes Endocrinol, 2015, 3 (5): 356-366.
|
| 9 |
Lind M, Svensson AM, Kosiborod M, et al. Glycemic control and excess mortality in type 1 diabetes [J]. N Engl J Med, 2014, 371 (21): 1972-1982.
|
| 10 |
Gerstein HC, Miller ME, Genuth S, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes [J]. N Engl J Med, 2011, 364 (9): 818-828.
|
| 11 |
Miller ME, Williamson JD, Gerstein HC, et al. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial [J]. Diabetes Care, 2014, 37 (3): 634-643.
|
| 12 |
Steineck I, Cederholm J, Eliasson B, et al. Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18, 168 people with type 1 diabetes: observational study [J]. BMJ, 2015, 350: h3234.
|
| 13 |
Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations [J]. Ann Intern Med, 2011, 154 (9): 602-613.
|
| 14 |
Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus [J]. N Engl J Med, 2013, 369 (14): 1317-1326.
|
| 15 |
Harris KB, McCarty DJ. Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus [J]. Ther Adv Endocrinol Metab, 2015, 6 (1): 3-18.
|
| 16 |
Hong J, Zhang Y, Lai S, et al. Response to comment on Hong et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care, 2013, 36: 1304-1311 [J]. Diabetes Care, 2014, 37 (1): e21.
|
| 17 |
Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial [J]. Lancet, 2009, 373 (9681): 2125-2135.
|
| 18 |
Glassock RJ, Bakris GL. Hypertension: Impact of blood pressure lowering in type 2 diabetes [J]. Nat Rev Nephrol, 2015, 11 (6): 320-321.
|
| 19 |
KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease [J]. Am J Kidney Dis, 2007, 49 (2 Suppl 2): S12-S154.
|
| 20 |
Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus [J]. N Engl J Med, 2010, 362 (17): 1575-1585.
|
| 21 |
Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis [J]. JAMA, 2015, 313 (6): 603-615.
|
| 22 |
Kidney disease: improving global outcomes (KDIGO) blood pressure work group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease [J]. Kidney Inter Suppl, 2012, 2(5): 337-414.
|
| 23 |
Roberts MA. Commentary on the KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease [J]. Nephrology (Carlton), 2014, 19 (1): 53-55.
|
| 24 |
Guideline development group. Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min) [J]. Nephrol Dial Transplant, 2015, 30(Suppl 2): ii1-142.
|
| 25 |
Luo Y, Yang SK, Zhou X, et al. Use of Ophiocordyceps sinensis (syn. Cordyceps sinensis) combined with angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB) versus ACEI/ARB alone in the treatment of diabetic kidney disease: a meta-analysis [J]. Ren Fail, 2015, 37 (4): 614-634.
|
| 26 |
Palmer SC, Mavridis D, Navarese E, et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis [J]. Lancet, 2015, 385 (9982): 2047-2056.
|
| 27 |
Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy [J]. N Engl J Med, 2013, 369 (20): 1892-1903.
|
| 28 |
Hao G, Wang Z, Guo R, et al. Effects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled studies [J]. BMC Cardiovasc Disord, 2014, 14: 148.
|
| 29 |
Yamamoto S, Okada Y, Mori H, et al. Type 2 diabetes mellitus complicated by hypertension in Japanese patients: switching treatment from high-dose angiotensin II receptor blockers to losartan plus hydrochlorothiazide [J]. Intern Med, 2014, 53 (12): 1283-1289.
|
| 30 |
Zoungas S, Chalmers J, Neal B, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes [J]. N Engl J Med, 2014, 371 (15): 1392-1406.
|
| 31 |
Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial [J]. Diabetes Care, 2013, 36 (9): 2508-2515.
|
| 32 |
Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis [J]. Ann Intern Med, 2013, 159 (4): 262-274.
|
| 33 |
Robinson LE, Holt TA, Rees K, et al. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis [J]. BMJ Open, 2013, 3(1): pii: e001986.
|
| 34 |
Nielsen SF, Nordestgaard BG. Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study [J]. Lancet Diabetes Endocrinol, 2014, 2 (11): 894-900.
|
| 35 |
Tonelli M, Wanner C. Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline [J]. Ann Intern Med, 2014, 160 (3): 182.
|
| 36 |
Colhoun HM, Betteridge DJ, Durrington PN, et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS) [J]. Am J Kidney Dis, 2009, 54 (5): 810-819.
|
| 37 |
Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial [J]. Lancet, 2011, 377 (9784): 2181-2192.
|
| 38 |
Hou W, Lv J, Perkovic V, et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis [J]. Eur Heart J, 2013, 34 (24): 1807-1817.
|
| 39 |
Krane V, Winkler K, Drechsler C, et al. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus [J]. Am J Kidney Dis, 2009, 54 (5): 902-911.
|
| 40 |
Marz W, Genser B, Drechsler C, et al. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis [J]. Clin J Am Soc Nephrol, 2011, 6 (6): 1316-1325.
|
| 41 |
Margolis KL, O′Connor PJ, Morgan TM, et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial [J]. Diabetes Care, 2014, 37 (6): 1721-1728.
|
| 42 |
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [J]. J Am Coll Cardiol, 2014, 63 (25 Pt B): 2889-2934.
|
| 43 |
American Diabetes Association. Standards of medical care in diabetes-2015 abridged for primary care providers [J]. Clin Diabetes, 2015, 33 (2): 97-111.
|
| 44 |
Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial [J]. JAMA, 2008, 300 (18): 2134-2141.
|
| 45 |
Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease [J]. BMJ, 2008, 337: a1840.
|
| 46 |
Ekstrom N, Cederholm J, Zethelius B, et al. Aspirin treatment and risk of first incident cardiovascular diseases in patients with type 2 diabetes: an observational study from the Swedish National Diabetes Register [J]. BMJ Open, 2013, 3(4) pii: e002688.
|
| 47 |
Sasso FC, Marfella R, Pagano A, et al. Lack of effect of aspirin in primary CV prevention in type 2 diabetic patients with nephropathy: results from 8 years follow-up of NID-2 study [J]. Acta Diabetol, 2015, 52 (2): 239-247.
|
| 48 |
de Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial [J]. Lancet, 2010, 376 (9752): 1543-1551.
|
| 49 |
Krairittichai U, Mahannopkul R, Bunnag S. An open label, randomized controlled study of oral calcitriol for the treatment of proteinuria in patients with diabetic kidney disease[J]. J Med Assoc Thai, 2012, 95(Suppl 3): S41-S47.
|
| 50 |
de Borst MH, Hajhosseiny R, Tamez H, et al. Active vitamin D treatment for reduction of residual proteinuria: a systematic review [J]. J Am Soc Nephrol, 2013, 24 (11): 1863-1871.
|
| 51 |
Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial [J]. JAMA, 2012, 307 (7): 674-684.
|
| 52 |
Shan D, Wu HM, Yuan QY, et al. Pentoxifylline for diabetic kidney disease [J]. Cochrane Database Syst Rev, 2012, 2: CD006800.
|
| 53 |
Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, et al. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial [J]. J Am Soc Nephrol, 2015, 26 (1): 220-229.
|
| 54 |
Pergola PE, Raskin P, Toto RD, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes [J]. N Engl J Med, 2011, 365 (4): 327-336.
|
| 55 |
de Zeeuw D, Akizawa T, Audhya P, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease [J]. N Engl J Med, 2013, 369 (26): 2492-2503.
|